Syndax Pharmaceuticals, Inc.
SNDX
$10.56
-$0.45-4.09%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.68M | 12.50M | 3.50M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.68M | 12.50M | 3.50M | -- | -- |
| Cost of Revenue | 80.70M | 65.09M | 44.34M | -- | 65.46M |
| Gross Profit | -73.02M | -52.59M | -40.84M | -- | -65.46M |
| SG&A Expenses | 37.69M | 31.11M | 29.06M | 23.02M | 22.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.05M | 102.08M | 77.72M | 79.51M | 77.91M |
| Operating Income | -96.37M | -89.58M | -74.22M | -79.51M | -77.91M |
| Income Before Tax | -94.17M | -84.13M | -68.06M | -72.40M | -72.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.17M | -84.13M | -68.06M | -72.40M | -72.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.17M | -84.13M | -68.06M | -72.40M | -72.47M |
| EBIT | -96.37M | -89.58M | -74.22M | -79.51M | -77.91M |
| EBITDA | -96.37M | -89.58M | -74.21M | -79.51M | -77.90M |
| EPS Basic | -1.10 | -0.98 | -0.80 | -0.85 | -1.00 |
| Normalized Basic EPS | -0.69 | -0.62 | -0.50 | -0.53 | -0.62 |
| EPS Diluted | -1.10 | -0.98 | -0.80 | -0.85 | -1.00 |
| Normalized Diluted EPS | -0.69 | -0.62 | -0.50 | -0.53 | -0.62 |
| Average Basic Shares Outstanding | 85.79M | 85.43M | 85.27M | 85.21M | 72.52M |
| Average Diluted Shares Outstanding | 85.79M | 85.43M | 85.27M | 85.21M | 72.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
